Phase Space Research

Guardant Health

GH · Investment summary · as of 29 July 2026

Priced close to what the business has demonstrated

Portfolio decision
Pending strategy review
Price · 29 July 2026
$143.48
12-month target
$133.31 -7%
Expected return
-7.1%
Next decision point
Date not announced

Business type: scaling but economically observable

Investment view

At $143.48, GH requires a 25% five-year revenue growth rate to justify its enterprise value — less than the business already delivers, at 30%.

The value rests on an exit multiple of 46.8x and a terminal operating margin of 20%. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.

Underwriting bridge

QuestionEvidence-based conclusion
What drives the business?Not determined — the operating driver is not stated in one place
What do we forecast?Revenue growth of 30% demonstrated; a terminal operating margin of 20%; an exit multiple of 46.8x.
What does Street forecast?Not determined — no consensus estimates are joined to this record
Where do we differ?On revenue growth, the difference between what the price requires and what the business has demonstrated is +4.4 percentage points.
What is it worth?Twelve-month target $133.31, -7% from the struck price. Scenario-weighted expected return net of costs -7.1%.
Why now?Date not announced — no dated event that would resolve the disagreement is on file

What must go right

Not determined — no falsifiable operating conditions are on file for this name, so the thesis cannot be reduced to a small number of testable claims

Catalysts and falsifiers

Date not announced — no dated event that would resolve the disagreement is on file

Risk and sell discipline

Impairment case

Not determined — no permanent-loss case with a named cause is on file; a bear valuation is not an impairment case

Fundamental invalidation

Not determined — no falsifiable invalidation conditions are on file, so this position cannot be risk-monitored

Price-based risk trigger

A daily close below $121.85 triggers an immediate review of the thesis and pauses additional buying. It is not an automatic sell unless a separate fundamental invalidation condition has been breached.

Upside sell discipline

On approach to the $133.31 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.

Investment criteria

CriteriaStatusInvestment meaning
QualityNot determinedIs the business worth owning under its declared economic type? Not established on the evidence on file.
ValuationNot determinedIs the operating path required by today's price achievable? Not established on the evidence on file.
LiquidityNot determinedCan the intended position be built and exited in the right vehicle? Not established on the evidence on file.
DownsideNot determinedWhat is the realistic permanent-loss case? Not established on the evidence on file.
MomentumNot determinedDoes price action support or complicate entry timing? Not established on the evidence on file.
CatalystNot determinedIs there a dated event that resolves the disagreement? Not established on the evidence on file.
ConsensusNot determinedIs the house-versus-Street disagreement identified and quantified? Not established on the evidence on file.

Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.

Bottom line

The strongest case for mispricing is that the business already delivers +4.4 percentage points more growth than the price requires. The most important unresolved uncertainty is whether this is a business worth owning at all — the evidence for its quality is not established. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $121.85, which forces an immediate review.